▽The New England Journal of Medicine: Research & Review Articles on Diseases & Clinical Practice ●06/15 21:42 Jun 15, 2025Meeting of the European Hematology AssociationMeasurable Residual Disease–Guided Therapy for CLLT. Munir and OthersAmong patients with chronic lymphocytic leukemia, undetectable MRD and progression-free survival were more common with ibrutinib–venetoclax than with ibrutinib alone or chemoimmunotherapy, with benefits sustained at 5 years.Original ArticleJun 13, 2025Meeting of the